Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled COPD and an eosinophilic phenotypeFollowing recent approvals in the EU and China, the US approval is ...
Sanofi’s Dupixent has been cleared for a chronic lung disorder in the US, in another milestone for the blockbuster drug after ...
Dupixent approved in the US as the first-ever biologic medicine for patients with COPD         Dupixent is indicated for the approximately 300,000 adults in the US with inadequately ...
Dupixent is indicated for the approximately 300,000 adults in the U.S. with inadequately controlled chronic obstructive pulmonary disease (COPD) ...
giving patients living with this devastating disease the chance to look forward to the potential of improved breathing and a life with fewer exacerbations,” Sanofi CEO Paul Hudson said in a statement.